BlackRock’s Organogenesis Holdings ORGO Stock Holding History

BlackRock’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.6M	Buy	4,899,751 +138,657	+3%	+$480K	﹤0.01%	3397
2025 Q4	$24.7M	Buy	4,761,094 +176,157	+4%	+$854K	﹤0.01%	2976
2025 Q3	$19.3M	Sell	4,584,937 -148,992	-3%	-$693K	﹤0.01%	3101
2025 Q2	$17.3M	Sell	4,733,929 -422,474	-8%	-$1.57M	﹤0.01%	3117
2025 Q1	$22.3M	Sell	5,156,403 -119,618	-2%	-$483K	﹤0.01%	2867
2024 Q4	$16.9M	Sell	5,276,021 -53,391	-1%	-$179K	﹤0.01%	3149
2024 Q3	$15.2M	Buy	5,329,412 +242,266	+5%	+$679K	﹤0.01%	3196
2024 Q2	$14.2M	Buy	5,087,146 +112,845	+2%	+$303K	﹤0.01%	3171
2024 Q1	$14.1M	Sell	4,974,301 -223,886	-4%	-$761K	﹤0.01%	3173
2023 Q4	$21.3M	Buy	5,198,187 +253,037	+5%	+$709K	﹤0.01%	2989
2023 Q3	$15.7M	Buy	4,945,150 +99,857	+2%	+$317K	﹤0.01%	3076
2023 Q2	$16.1M	Buy	4,845,293 +356,680	+8%	+$1.05M	﹤0.01%	3170
2023 Q1	$9.56M	Sell	4,488,613 -6,614,577	-60%	-$16.3M	﹤0.01%	3341
2022 Q4	$29.9M	Buy	11,103,190 +566,429	+5%	+$1.65M	﹤0.01%	2806
2022 Q3	$34.1M	Buy	10,536,761 +861,588	+9%	+$3.89M	﹤0.01%	2721
2022 Q2	$47.2M	Buy	9,675,173 +22,985	+0.2%	+$141K	﹤0.01%	2539
2022 Q1	$73.6M	Buy	9,652,188 +1,412,356	+17%	+$10.9M	﹤0.01%	2335
2021 Q4	$76.1M	Buy	8,239,832 +165,724	+2%	+$1.76M	﹤0.01%	2386
2021 Q3	$115M	Buy	8,074,108 +1,052,935	+15%	+$16.4M	﹤0.01%	2122
2021 Q2	$117M	Buy	7,021,173 +4,730,593	+207%	+$88.2M	﹤0.01%	2161
2021 Q1	$41.7M	Buy	2,290,580 +1,026,183	+81%	+$13.9M	﹤0.01%	2740
2020 Q4	$9.52M	Buy	1,264,397 +206,412	+20%	+$980K	﹤0.01%	3385
2020 Q3	$4.06M	Sell	1,057,985 -4,398	-0.4%	-$17.4K	﹤0.01%	3650
2020 Q2	$4.08M	Buy	1,062,383 +411,298	+63%	+$1.48M	﹤0.01%	3601
2020 Q1	$2.1M	Buy	651,085 +23,052	+4%	+$98.7K	﹤0.01%	3641
2019 Q4	$3.02M	Buy	628,033 +35,645	+6%	+$226K	﹤0.01%	3653
2019 Q3	$3.89M	Buy	592,388 +37,550	+7%	+$209K	﹤0.01%	3552
2019 Q2	$4.22M	Buy	554,838 +486,870	+716%	+$3.58M	﹤0.01%	3574
2019 Q1	$510K	Buy	+67,968	New	+$1.36M	﹤0.01%	4097

Other funds holding ORGO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock's ORGO Position: Q1 2026 in Review

BlackRock increased its Organogenesis Holdings (ORGO) stake by 2.9% in Q1 2026, buying an estimated $480K and bringing the position to 4,899,751 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3397.

BlackRock first reported a position in ORGO in Q1 2019 and has held it in 29 quarters since. The position peaked at $117M in Q2 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

BlackRock held 4,899,751 shares of Organogenesis Holdings worth $11.6M as of Q1 2026.
BlackRock bought 138,657 Organogenesis Holdings shares in Q1 2026, an estimated $480K.
Organogenesis Holdings made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3397 holding.
BlackRock first reported a position in Organogenesis Holdings in Q1 2019 and has held it in 29 quarters since.
BlackRock's Organogenesis Holdings position peaked at $117M in Q2 2021.
121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.